To further validate the utility of iMyoblasts for muscle disease research, we investigated the potential ex vivo and in vivo modeling applications of iMyoblasts from iPSCs derived from patients with FKRP dystroglycanopathies and LGMDR7 muscular dystrophy (Figure 9). Here, FKRP is linked to neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.